Shares of Balchem Co. (NASDAQ:BCPC) have been assigned an average rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $120.67.
A number of equities analysts have recently commented on the company. BidaskClub raised Balchem from a “sell” rating to a “hold” rating in a report on Thursday. Sidoti raised Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price target for the company in a report on Tuesday. HC Wainwright set a $140.00 price target on Balchem and gave the stock a “buy” rating in a report on Monday. ValuEngine raised Balchem from a “hold” rating to a “buy” rating in a report on Thursday, August 30th. Finally, Pivotal Research boosted their price target on Balchem from $85.00 to $95.00 and gave the stock a “hold” rating in a report on Friday, August 3rd.
Balchem stock opened at $100.34 on Tuesday. The company has a quick ratio of 2.82, a current ratio of 3.98 and a debt-to-equity ratio of 0.33. Balchem has a 52 week low of $70.23 and a 52 week high of $117.79. The firm has a market cap of $3.25 billion, a PE ratio of 35.62 and a beta of 0.83.
Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, August 3rd. The basic materials company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Balchem had a return on equity of 13.78% and a net margin of 15.28%. The company had revenue of $163.70 million during the quarter, compared to analysts’ expectations of $163.20 million. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. As a group, research analysts forecast that Balchem will post 2.45 EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. Zeke Capital Advisors LLC bought a new stake in Balchem during the 2nd quarter worth $203,000. Cubist Systematic Strategies LLC bought a new stake in Balchem during the 2nd quarter worth $218,000. Granahan Investment Management Inc. MA bought a new stake in Balchem during the 2nd quarter worth $224,000. Sigma Planning Corp bought a new stake in Balchem during the 2nd quarter worth $229,000. Finally, CIBC Asset Management Inc bought a new stake in Balchem during the 2nd quarter worth $240,000. 88.21% of the stock is owned by institutional investors.
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Recommended Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.